Withaferin A enhances sorafenib sensitivity in sorafenib-resistant hepatocellular carcinoma cells by regulating the Keap1/Nrf2-associated epithelial-to-mesenchymal transition (EMT) and ferroptosis[44]. Here, KEAP1 is linked to hepatocellular carcinoma.